The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Gerrit Los named vice president of pharmacology at AnaptysBio Inc.

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

GERRIT LOS was named vice president of pharmacology at AnaptysBio Inc.

Los will lead translational biology across the company’s antibody pipeline, including programs focused in immuno-oncology. Los will report to Macro Londei, AnaptysBio’s chief development officer.

Los joins AnaptysBio from Five Prime Therapeutics, where he led translational medicine across several immuno-oncology related biologics. Prior to Five Prime, Los was head of cancer biology at Pfizer, where he directed teams responsible for the development of several targeted cancer therapeutics, including crizotinib, axitinib and palbociclib.

Prior to Pfizer, Los was an adjunct professor at the University of California San Diego where his work focused on identifying response markers in cancer.

Table of Contents

YOU MAY BE INTERESTED IN

Pfizer seeks to improve breast cancer outcomes in Sub-Saharan Africa
With help from Conquer Cancer’s EveryGrant and ASCO’s Sub-Saharan Africa Regional Council, Pfizer awards grants to seven countries

Pfizer External Research & Grants’ “Improving Breast Cancer Quality of Care via Meaningful Capacity Building in Sub-Saharan Africa,” powered by EveryGrant, has announced grants totaling more than $900,000 for addressing inequities and improving the quality of breast cancer care in Sub-Saharan Africa.
By Claire Marie Porter
ClinicalTrials & Tribulations

The other side of the patient portal: Reflections from a cancer center leader

It started innocuously enough. I looked in the mirror and noticed a pigmented area on my scalp just into the hairline. Like many patients, thoughts started running through my head: “Maybe it’s nothing.” Looking at my Outlook calendar, it was packed morning-to-night with meetings, patients, and travel, so I decided I would get that spot checked out the minute I had “time.” 
By Ruben A. Mesa
Cancer Policy

A farewell post by an unidentified NCI employee triggers an accusation of “undermining the Trump administration”

In the morning of May 28, presumably before turning off the lights and closing the office door, someone at the now defunct NCI Office of Communications and Public Liaision decided to post a farewell message to the cancer community.  The message, posted on multiple social media accounts, read: We’re taking a pause here - but...

By Jacquelyn Cobb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account